Kyverna Therapeutics (KYTX) Cash from Operations (2023 - 2026)

Kyverna Therapeutics (KYTX) has 4 years of Cash from Operations data on file, last reported at 41600000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations rose 7.35% year-over-year to 41600000.0; the trailing twelve-month figure through Mar 2026 stood at 150400000.0 (down 12.51% YoY), and the FY2025 full-year result was 153700000.0, down 34.47% from the prior year.
• Cash from Operations for Q1 2026 stood at 41600000.0, down from 33515000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 11132000.0 in Q3 2023 and bottomed at 44900000.0 in Q1 2025.
• The 4-year median for Cash from Operations is 27489000.0 (2024), against an average of 27846153.85.
• The widest annual swing landed in 2024, when Cash from Operations tumbled 146.94%; it then advanced 9.69% in 2025.
• A 4-year view of Cash from Operations shows it stood at 18553000.0 in 2023, then slumped by 100.03% to 37111000.0 in 2024, then climbed by 9.69% to 33515000.0 in 2025, then slipped by 24.12% to 41600000.0 in 2026.
• The last three Cash from Operations figures came in at 41600000.0 (Q1 2026), 33515000.0 (Q4 2025), and 43321000.0 (Q3 2025), per Business Quant data.

Peer Comparison